Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
55
PPH Quote, Financials, Valuation and Earnings
Last price:
$104.27
Seasonality move
:
0.32%
Day range:
$104.03 - $104.47
52-week range:
$77.67 - $104.47
Dividend yield:
1.86%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
127.6K
Avg. volume:
412.1K
1-year change:
18.93%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
$104.30 | -- | -- | -- | $0.39 | 1.86% | -- |
|
AGNG
Global X Aging Population ETF
|
$36.42 | -- | -- | -- | $0.14 | 0.79% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$47.65 | -- | -- | -- | $0.03 | 0.07% | -- |
|
HEAL
Global X HealthTech ETF
|
$29.94 | -- | -- | -- | $0.02 | 0.08% | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
$32.62 | -- | -- | -- | $0.32 | 0.98% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$26.94 | -- | -- | -- | $0.16 | 1.15% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.233 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.484 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.886 | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | 1.781 | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | 1.095 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.936 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
VanEck Pharmaceutical ETF vs. Competitors
-
Which has Higher Returns PPH or AGNG?
Global X Aging Population ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About PPH or AGNG?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than Global X Aging Population ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is PPH or AGNG More Risky?
VanEck Pharmaceutical ETF has a beta of 0.549, which suggesting that the stock is 45.102% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.722%.
-
Which is a Better Dividend Stock PPH or AGNG?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 1.86%. Global X Aging Population ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $0.14 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or AGNG?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns PPH or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About PPH or GNOM?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is PPH or GNOM More Risky?
VanEck Pharmaceutical ETF has a beta of 0.549, which suggesting that the stock is 45.102% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.563%.
-
Which is a Better Dividend Stock PPH or GNOM?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 1.86%. Global X Genomics & Biotechnology ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or GNOM?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns PPH or HEAL?
Global X HealthTech ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat Global X HealthTech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- HEALGlobal X HealthTech ETF-- -- -- -
What do Analysts Say About PPH or HEAL?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X HealthTech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than Global X HealthTech ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than Global X HealthTech ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 HEALGlobal X HealthTech ETF0 0 0 -
Is PPH or HEAL More Risky?
VanEck Pharmaceutical ETF has a beta of 0.549, which suggesting that the stock is 45.102% less volatile than S&P 500. In comparison Global X HealthTech ETF has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.903%.
-
Which is a Better Dividend Stock PPH or HEAL?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 1.86%. Global X HealthTech ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. Global X HealthTech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or HEAL?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than Global X HealthTech ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than Global X HealthTech ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while Global X HealthTech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for Global X HealthTech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- HEALGlobal X HealthTech ETF-- -- -- --
-
Which has Higher Returns PPH or IBRN?
iShares Neuroscience and Healthcare ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat iShares Neuroscience and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- -
What do Analysts Say About PPH or IBRN?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Neuroscience and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than iShares Neuroscience and Healthcare ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than iShares Neuroscience and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 IBRNiShares Neuroscience and Healthcare ETF0 0 0 -
Is PPH or IBRN More Risky?
VanEck Pharmaceutical ETF has a beta of 0.549, which suggesting that the stock is 45.102% less volatile than S&P 500. In comparison iShares Neuroscience and Healthcare ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PPH or IBRN?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 1.86%. iShares Neuroscience and Healthcare ETF offers a yield of 0.98% to investors and pays a quarterly dividend of $0.32 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. iShares Neuroscience and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or IBRN?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than iShares Neuroscience and Healthcare ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than iShares Neuroscience and Healthcare ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while iShares Neuroscience and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for iShares Neuroscience and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- --
-
Which has Higher Returns PPH or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About PPH or IDNA?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is PPH or IDNA More Risky?
VanEck Pharmaceutical ETF has a beta of 0.549, which suggesting that the stock is 45.102% less volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.579%.
-
Which is a Better Dividend Stock PPH or IDNA?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 1.86%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.16 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or IDNA?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
